Identifying more than 500 genetic proverbies on bone mineral density, researchers are expecting new opportunities to develop new drugs to prevent or cure osteoporosis
Source: McGill Reporter
A new research led by researchers from the Lady Davis Institute (LDI) at the Jewish General Hospital (JGH) has been successful in creating atlases of genetic cases related to the estimated bone mineral congestion (BMD), one of the main points of relevance to clinical factors in diagnosing osteoporosis. The paper, published in Nature Genetics, identifies 518 loci genome-wide, and 301 have been detected again, Defines 20% of the genetic difference associated with osteoporosis. Having recognized so many genetic issues, there is a good commitment to the development of a new system to handle the disease and reduce the risk of broken.
"Our conclusions represent important progress in identifying drug development opportunities," and explains Dr. Brent Richards, Chief Investigator, Geneticist at the LDI Center for Clinical Epidemiology; Treating patients with osteoporosis than using JGH. "This set of genetic changes that impact on BMDs provide drug targets that may be helpful in preventing osteoporotic breakdown."
Osteoporosis is a very common age condition, marked by a continued reduction of bone strength, which means there is a risk of breaking. Especially in older patients, breakdown can cause adverse effects, including risk of dying. Among all those who suffer, there is a breach; Greater Hospital Obesity and Extensible Rehabilitation. As the population grows, it is harder for the prevention measures to be developed.
"There are not many curative options at this time," said Dr. Richards, McGill University's General Medicine, Human Genetics, and Epidemiology and Biostatistics, "and many patients with a risk in Breach causes current treatment due to frightening friction. Although it is always better to stop the handling. We can create orders that & # 39 , bone builders, but they are casually binding. We have a medicine that prevents the prevention of a bone, but they need to be put on a tight record. As a result, the number of people to be treated to them, but not high. So, we believe we will be more successful in helping patients to follow a medicine order when it can make it easier. "
This is the largest study of genetic confirmation of osteoporosis, which has always been done. Assessing more than 426,000 people in the UK Biobank. After analyzing the data, the researchers have further expanded their output for a set of genes that are strongly strengthened for known drug targets. The smaller set of target genes allow for drug developers to narrow the investigation to solve the clinical problem in preventing the breakdown of those who are left to osteoporotic breakdown. Animal models have already proven some of these genera.
"Although we have found many of the genetic causes associated with BMD, the type of arthritis that we have in genetics should allow us to enter on those features that can most affect the development of bone congestion and reduce the risk of broken, "said Dr John Morris, also from LDI and McGill University, the main author of the study.
"Atlas of genetic influence on osteoporosis in humans and mice," by John A. Morris et al Nature Genetics
For media questions, and interview with Dr. Richards, contact:
Research Communications Officer
Lady Davis Institute
Telephone: 514-340-8222 x 28661
For more information about Lady Davis Institute: http://www.ladydavis.ca
For more information about the Jewish General Hospital: http://www.jgh.ca
January 3, 2019